Document is current
Any future updates will be listed below
-
Authors
Stenzinger, Albrecht https://orcid.org/0000-0003-1001-103X
Westphalen, C. Benedikt
Budczies, Jan https://orcid.org/0000-0002-6668-5327
Kazdal, Daniel https://orcid.org/0000-0001-8187-3281
Ploeger, Carolin
Altbürger, Christian
Evert, Matthias
Malek, Nisar
Schirmacher, Peter
Klauschen, Frederick
- License Information
-
More Information
Article History
Received: 13 December 2024
Revised: 3 March 2025
Accepted: 28 March 2025
First Online: 18 April 2025
Competing interests
: Albrecht Stenzinger received honoraria for participation in advisory boards/speaker’s bureau from Aignostics, Amgen, Astellas, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Sanofi, Servier, Takeda and Thermo Fisher Scientific and research funding from Bayer, BMS, Chugai and Incyte. Jan Budczies received consulting fees from MSD and a research grant by the German Cancer Aid (to the institution). Daniel Kazdal received personal and speaker fees from Agilent, AstraZeneca, BMS, Illumina, Incyte, Eli Lilly, Pfizer and Takeda. Peter Schirmacher received consultation fees from BMS, MSD, Incyte, Eisai, Janssen and Roche and research funding to institutions from Incyte, BMS, Chugai. C. Benedikt Westphalen, Carolin Ploeger, Christian Altbürger, Matthias Evert, Nisar Malek and Frederick Klauschen declared no conflicts of interest.
